The use of tranexamic acid (TXA) in patients undergoing oncology and other major noncardiac surgeries reduces the administration of red blood cell (RBC) transfusions across patient and surgical ...
Topical and intravenous tranexamic acid (TXA) were found to significantly reduce blood loss compared with placebo in patients who have undergone bone surgery, suggesting that both administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback